IBDEI07Z ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3592,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,3592,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,3593,0)
 ;;=289.9^^33^281^107
 ;;^UTILITY(U,$J,358.3,3593,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3593,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,3593,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,3593,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,3594,0)
 ;;=451.9^^33^281^108
 ;;^UTILITY(U,$J,358.3,3594,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3594,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,3594,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,3594,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,3595,0)
 ;;=446.6^^33^281^109
 ;;^UTILITY(U,$J,358.3,3595,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3595,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,3595,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(TTP)
 ;;^UTILITY(U,$J,358.3,3595,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,3596,0)
 ;;=286.4^^33^281^112
 ;;^UTILITY(U,$J,358.3,3596,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3596,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,3596,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,3596,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,3597,0)
 ;;=204.00^^33^281^2
 ;;^UTILITY(U,$J,358.3,3597,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3597,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,3597,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,3597,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,3598,0)
 ;;=204.01^^33^281^1
 ;;^UTILITY(U,$J,358.3,3598,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3598,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,3598,1,5,0)
 ;;=5^ALL In Remission
 ;;^UTILITY(U,$J,358.3,3598,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,3599,0)
 ;;=204.10^^33^281^13
 ;;^UTILITY(U,$J,358.3,3599,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3599,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,3599,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,3599,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,3600,0)
 ;;=204.11^^33^281^12
 ;;^UTILITY(U,$J,358.3,3600,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3600,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,3600,1,5,0)
 ;;=5^CLL In Remission
 ;;^UTILITY(U,$J,358.3,3600,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,3601,0)
 ;;=201.90^^33^281^74
 ;;^UTILITY(U,$J,358.3,3601,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3601,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,3601,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,3601,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,3602,0)
 ;;=785.6^^33^281^80
 ;;^UTILITY(U,$J,358.3,3602,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3602,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,3602,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,3602,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,3603,0)
 ;;=200.20^^33^281^81
 ;;^UTILITY(U,$J,358.3,3603,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3603,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,3603,1,5,0)
 ;;=5^Lymphoma, Burkitt's, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,3603,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,3604,0)
 ;;=202.00^^33^281^83
 ;;^UTILITY(U,$J,358.3,3604,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3604,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,3604,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,3604,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,3605,0)
 ;;=200.10^^33^281^82
 ;;^UTILITY(U,$J,358.3,3605,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3605,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,3605,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,3605,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,3606,0)
 ;;=273.3^^33^281^84
 ;;^UTILITY(U,$J,358.3,3606,1,0)
 ;;=^358.31IA^5^2
